U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C21H45N3
Molecular Weight 339.6021
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXETIDINE

SMILES

CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1

InChI

InChIKey=DTOUUUZOYKYHEP-UHFFFAOYSA-N
InChI=1S/C21H45N3/c1-6-10-12-19(8-3)14-23-16-21(5,22)17-24(18-23)15-20(9-4)13-11-7-2/h19-20H,6-18,22H2,1-5H3

HIDE SMILES / InChI

Molecular Formula C21H45N3
Molecular Weight 339.6021
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/11917691

Hexetidine is very safe oral antiseptic with broad antibacterial and antifungal activity in vivo and in vitro. It has local-anesthetics, astringent and deodorant activity. Also, it has very strong antiplac effects. Resistention of microorganisms on hexetidine is short and transient. These characteristics give important therapeutic role in treatment of oral infections. In the UK, hexetidine is the active ingredient in the medicated mouthwash branded Oraldene. Oraldene contains 0.1 g/100 ml of hexetidine. In Germany, hexetidine is used for vaginal antisepsis.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Oraldene

Approved Use

Unknown
Curative
Oraldene

Approved Use

Unknown
Curative
Oraldene

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
0.1 % 1 times / day multiple, oromucosal
Dose: 0.1 %, 1 times / day
Route: oromucosal
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
unhealthy, 38.2 years (range: 18–61 years)
n = 46
Health Status: unhealthy
Condition: supragingival plaque | gingivitis
Age Group: 38.2 years (range: 18–61 years)
Sex: M+F
Population Size: 46
Sources:
10 mg 1 times / day multiple, vaginal
Dose: 10 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 100
Health Status: unhealthy
Sex: F
Population Size: 100
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Analytical profile of purified hexetidine (author's transl)].
1975
[Disturbances of taste from oral disinfectants (author's transl)].
1978 Oct
The erosive effects of some mouthrinses on enamel. A study in situ.
2001 Apr
The concomitant development of poly(vinyl chloride)-related biofilm and antimicrobial resistance in relation to ventilator-associated pneumonia.
2001 Oct
A comparative study in vivo of the therapeutic effect of triclosan, hexetidine and chitosan.
2002
[Hexetidine--an oral antiseptic].
2002
Nonaqueous capillary electrophoretic analysis of hexetidine in a commercial liquid formulation.
2002 Apr
Physicochemical characterization of hexetidine-impregnated endotracheal tube poly(vinyl chloride) and resistance to adherence of respiratory bacterial pathogens.
2002 Jun
An in vitro oral biofilm model for comparing the efficacy of antimicrobial mouthrinses.
2002 Mar-Apr
Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor.
2002 Sep
Antiplaque and antigingivitis effectiveness of a hexetidine mouthwash.
2003 Jul
Clinical study on the effectiveness and side effects of hexetidine and chlorhexidine mouthrinses versus a negative control.
2005 Sep
Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis.
2005 Sep
[Stopangin in the treatment of pharyngeal inflammation].
2006
Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis.
2006 Jul
Mucocutaneous lesions of Behcet's disease.
2007 Aug 31
[Efficacy of an antiseptic dialysis of purulent wounds in the dentofacial region with hyvalix].
2007 Jul-Sep
[Combined local therapy in oropharyngeal diseases].
2008
Efficacy of vaginal misoprostol before hysteroscopy for cervical priming in patients who have undergone cesarean section and no vaginal deliveries.
2008 Jul-Aug
Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons.
2009 Sep 23
Parotid gland swelling following mouthrinse use.
2010 Nov
The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model - a cross-over study.
2010 Nov
The effect of hexetidine mouthwash on the prevention of plaque and gingival inflammation: a systematic review.
2011 Aug
Patents

Sample Use Guides

mouthwash
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: all information about in vitro activity in german
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:19:20 GMT 2023
Edited
by admin
on Sat Dec 16 17:19:20 GMT 2023
Record UNII
852A84Y8LS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXETIDINE
EP   HSDB   INCI   INN   MART.   MI   WHO-DD  
INN   INCI  
Official Name English
HEXETIDINE [MART.]
Common Name English
HEXETIDINE [INCI]
Common Name English
STERISIL
Brand Name English
HEXETIDINE [EP MONOGRAPH]
Common Name English
NSC-17764
Code English
HEXETIDINE [HSDB]
Common Name English
Hexetidine [WHO-DD]
Common Name English
hexetidine [INN]
Common Name English
HEXETIDINE [MI]
Common Name English
5-AMINO-1,3-BIS(2-ETHYLHEXYL)HEXAHYDRO-5-METHYLPYRIMIDINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C28394
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
WHO-ATC A01AB12
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
WHO-ATC G01AX16
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
WHO-VATC QA01AB12
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
Code System Code Type Description
MERCK INDEX
m6009
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY Merck Index
SMS_ID
100000092531
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
MESH
D006590
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
NCI_THESAURUS
C77049
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
RXCUI
5301
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
205-513-5
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
CAS
141-94-6
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
WIKIPEDIA
Hexetidine
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
FDA UNII
852A84Y8LS
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
PUBCHEM
3607
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
DRUG CENTRAL
3277
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045297
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
DRUG BANK
DB08958
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
INN
522
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
HSDB
7828
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
EVMPD
SUB08037MIG
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
NSC
17764
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
ChEMBL
CHEMBL144673
Created by admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY